η-Secretase processing of APP inhibits neuronal activity in the hippocampus

Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-β peptide. Two principal physiological pathways either prevent or promote amyloid-β generation from its precursor, β-amyloid precursor protein (APP), in a competitive manner. Although APP processing has been studied in great detail, unknown proteolytic events seem to hinder stoichiometric analyses of APP metabolism in vivo. Here we describe a new physiological APP processing pathway, which generates proteolytic fragments capable of inhibiting neuronal activity within the hippocampus. We identify higher molecular mass carboxy-terminal fragments (CTFs) of APP, termed CTF-η, in addition to the long-known CTF-α and CTF-β fragments generated by the α- and β-secretases ADAM10 (a disintegrin and metalloproteinase 10) and BACE1 (β-site APP cleaving enzyme 1), respectively. CTF-η generation is mediated in part by membrane-bound matrix metalloproteinases such as MT5-MMP, referred to as η-secretase activity. η-Secretase cleavage occurs primarily at amino acids 504–505 of APP695, releasing a truncated ectodomain. After shedding of this ectodomain, CTF-η is further processed by ADAM10 and BACE1 to release long and short Aη peptides (termed Aη-α and Aη-β). CTFs produced by η-secretase are enriched in dystrophic neurites in an AD mouse model and in human AD brains. Genetic and pharmacological inhibition of BACE1 activity results in robust accumulation of CTF-η and Aη-α. In mice treated with a potent BACE1 inhibitor, hippocampal long-term potentiation was reduced. Notably, when recombinant or synthetic Aη-α was applied on hippocampal slices ex vivo, long-term potentiation was lowered. Furthermore, in vivo single-cell two-photon calcium imaging showed that hippocampal neuronal activity was attenuated by Aη-α. These findings not only demonstrate a major functionally relevant APP processing pathway, but may also indicate potential translational relevance for therapeutic strategies targeting APP processing.

[1]  B. Winblad,et al.  Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation , 1995, Neuroscience Letters.

[2]  G. Westmeyer,et al.  Dimerization of β-Site β-Amyloid Precursor Protein-cleaving Enzyme* , 2004, Journal of Biological Chemistry.

[3]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[4]  C. Overall,et al.  Metalloprotease Meprin β Generates Nontoxic N-terminal Amyloid Precursor Protein Fragments in Vivo* , 2011, The Journal of Biological Chemistry.

[5]  M. Mann,et al.  Higher-energy C-trap dissociation for peptide modification analysis , 2007, Nature Methods.

[6]  J. Teller,et al.  Diethylamine extraction of proteins and peptides isolated with a mono-phasic solution of phenol and guanidine isothiocyanate. , 2006, Journal of biochemical and biophysical methods.

[7]  Marc Tessier-Lavigne,et al.  APP binds DR6 to trigger axon pruning and neuron death via distinct caspases , 2009, Nature.

[8]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[9]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[10]  K. Blennow,et al.  Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[11]  Bert Sakmann,et al.  Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease , 2012, Proceedings of the National Academy of Sciences.

[12]  Kristopher L. Nazor,et al.  Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.

[13]  Junmin Peng,et al.  Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser Capture Microdissection*[boxs] , 2004, Journal of Biological Chemistry.

[14]  Hiroyuki Arai,et al.  Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum , 2001, The European journal of neuroscience.

[15]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[16]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[17]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[18]  L. Ozmen,et al.  Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice , 2014, The Journal of Neuroscience.

[19]  C. Stosiek,et al.  In vivo two-photon calcium imaging of neuronal networks , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[21]  S. Kaech,et al.  Culturing hippocampal neurons , 2006, Nature Protocols.

[22]  R. Cappai,et al.  Identification of a novel amyloid precursor protein processing pathway that generates secreted N‐terminal fragments , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Shaomin Li,et al.  Secreted Amyloid β-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity , 2014, Biochemistry.

[24]  Munirah Ahmad,et al.  Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. , 2006, Journal of biochemistry.

[25]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[26]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[27]  S. Squazzo,et al.  Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.

[28]  Thomas Rülicke,et al.  Behavioral and anatomical deficits in mice homozygous for a modified β-amyloid precursor protein gene , 1994, Cell.

[29]  A. Cattaneo,et al.  Transgenic Mice with Chronic NGF Deprivation and Alzheimer's Disease-Like Pathology Display Hippocampal Region-Specific Impairments in Short- and Long-Term Plasticities , 2010, The Journal of Neuroscience.

[30]  R. Bateman,et al.  CNS Amyloid-β, Soluble APP-α and -β Kinetics during BACE Inhibition , 2014, The Journal of Neuroscience.

[31]  S. Younkin,et al.  Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. , 1992, Science.

[32]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[33]  K. Miyazaki,et al.  Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. , 2003, Biochemistry.

[34]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[35]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[36]  C. Haass Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[37]  Peter Kirwan,et al.  Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses , 2012, Nature Neuroscience.

[38]  U. Schepers,et al.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons , 2012, The EMBO journal.

[39]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[40]  D. Selkoe,et al.  Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.

[41]  C. López-Otín,et al.  Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation , 2009, Proceedings of the National Academy of Sciences.

[42]  Matthias Mann,et al.  The Q Exactive HF, a Benchtop Mass Spectrometer with a Pre-filter, High-performance Quadrupole and an Ultra-high-field Orbitrap Analyzer* , 2014, Molecular & Cellular Proteomics.

[43]  R. W. Rauser,et al.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[45]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[46]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[47]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[48]  J. Hardy,et al.  Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family , 1994, Neuroscience Letters.

[49]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[50]  F. J. Livesey,et al.  Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks , 2012, Nature Protocols.

[51]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[52]  D. Selkoe,et al.  beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. , 1993, The Journal of biological chemistry.

[53]  B. de Strooper,et al.  The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo* , 2012, The Journal of Biological Chemistry.